(Q37055015)

PubMed publication ID

18 August 2017

1 reference

title

Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

0 references

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

author name string

Arne Schäfer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

Jochen Seufert

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

Michael R Kraus

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

publication date

1 January 2007

1 reference

PubMed publication ID

18188838

International Journal of Methods in Psychiatric Research

18 August 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

page(s)

186-201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

An Inventory for Measuring Depression

13 May 2020

cites work

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

21 January 2018

1 reference

A quantitative assessment of depression and thyroid dysfunction secondary to interferon-alpha therapy in patients with hepatitis C.

21 January 2018

1 reference

Factors influencing the self-rating depression scale.

21 January 2018

1 reference

Self-rating depression scale in an outpatient clinic. Further validation of the SDS.

21 January 2018

1 reference

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

1 reference

12 December 2020

Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study

1 reference

12 December 2020

Hepatitis C, interferon alfa, and depression

1 reference

12 December 2020

Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors.

1 reference

12 December 2020

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Neurobehavioral effects of interferon therapy

1 reference

12 December 2020

Side effects of therapy of hepatitis C and their management

1 reference

12 December 2020

Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state.

1 reference

12 December 2020

Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon

1 reference

12 December 2020

Early increase in vegetative symptoms predicts IFN-alpha-induced cognitive-depressive changes.

1 reference

12 December 2020

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

1 reference

12 December 2020

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

12 December 2020

Depression during therapy with interferon alpha--how long should an antidepressant treatment last?

1 reference

12 December 2020

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

1 reference

12 December 2020

Psychiatric complications of long-term interferon alfa therapy

1 reference

12 December 2020

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

1 reference

12 December 2020

Prevalence of hepatitis C among psychiatric patients in the public sector.

1 reference

12 December 2020

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy

1 reference

12 December 2020

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

12 December 2020

Incidence of interferon alfa-induced depression in patients with chronic hepatitis C

1 reference

12 December 2020

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

12 December 2020

Psychiatric side effects of interferon-beta in multiple sclerosis

1 reference

12 December 2020

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

12 December 2020

Depression, anemia and health-related quality of life in chronic hepatitis C.

1 reference

12 December 2020

Interferon-induced depression: prevalence and management

1 reference

12 December 2020

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

1 reference

12 December 2020

Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.

1 reference

12 December 2020

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life.

1 reference

12 December 2020

Side effects of therapy for chronic hepatitis C.

1 reference

12 December 2020

The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt

1 reference

12 December 2020

Central nervous system changes in hepatitis C virus infection

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

The hospital anxiety and depression scale

1 reference

12 December 2020

Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study

1 reference

12 December 2020

Interferon-induced depression: strategies in treatment.

1 reference

12 December 2020

Screening depressed patients in family practice. A rapid technic

1 reference

12 December 2020

Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Suicidal impulses in patients with chronic viral hepatitis C during or after therapy with interferon alpha

1 reference

12 December 2020

Suicide associated with alfa-interferon therapy for chronic viral hepatitis

1 reference

12 December 2020

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

12 December 2020

Paroxetine for the prevention of depression induced by interferon alfa

1 reference

12 December 2020

Interferon Alpha-Induced Depression in Chronic Hepatitis C Patients: Comparison between Different Types of Interferon Alpha

1 reference

12 December 2020

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

12 December 2020

Treatment of hepatitis C

1 reference

12 December 2020

Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C

1 reference

12 December 2020

Depression from interferon therapy in patients with hepatitis C

1 reference

12 December 2020

The phenomenology and treatment of interferon-induced depression.

1 reference

12 December 2020

Assessment of depression in cancer patients

1 reference

12 December 2020

Manic episodes in two patients treated with interferon alpha

1 reference

12 December 2020

Global epidemiology of hepatitis C virus infection

1 reference

12 December 2020

High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts

1 reference

12 December 2020

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Depression in the Normal Aged

1 reference

12 December 2020

Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C.

1 reference

12 December 2020

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

1 reference

12 December 2020

Role of the psychiatrist in the care of patients with hepatitis C and HIV/AIDS.

1 reference

12 December 2020

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

1 reference

12 December 2020

Evidence-informed assessment and treatment of depression in HCV and interferon-treated patients

1 reference

12 December 2020

Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test

1 reference

12 December 2020

Mood disorders associated with interferon treatment: theoretical and practical considerations

1 reference

12 December 2020

Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy

1 reference

12 December 2020

Identifiers

DOI

10.1002/MPR.229

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6878515&resulttype=core&format=json

13 May 2020

PubMed publication ID

18188838

1 reference